Drug Type AAV based gene therapy |
Synonyms AAV1-hOTOF, Dual recombinant adeno-associated viral vectors encoding the human otoferlin gene, RRG-OTOF + [2] |
Target |
Action modulators |
Mechanism OTOF modulators(otoferlin modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
RegulationOrphan Drug (United States) |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Deafness | Phase 1 | China | 17 Nov 2022 | |
| Deafness | Phase 1 | China | 17 Nov 2022 | |
| Deafness, Autosomal Recessive 9 | Phase 1 | China | 01 Sep 2022 | |
| Hearing Loss | IND Approval | United States | - |





